Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President and Representative Director: Masayuki Kobayashi) announced on August 29 that the company has entered into an agreement to invest up to US$30 million in Remiges Biopharma Fund II, LP a biopharma venture capital fund formed by Remiges Ventures, Inc. Taiho Pharmaceutical invested the same amount in the Remiges BioPharma Fund I established in 2014.

As students are returning for the semester at Johns Hopkins University, a new accelerator is launching for those who are forming new ventures.

Liftstream, a U.K.-based executive recruiting firm, released an oft referenced report called “A Public Reality for Women in Biotech Boardrooms” in 2016. Lifstream’s research found that only 7 to 9 percent of biotech CEOs were women, less than 11 percent of board seats were held by females and 98 percent of board chair positions were held by men. The report surveyed 177 publicly-listed biotechs that went through the IPO process from 2012 to 2015.

The rare autoimmune disease compromises the central nervous system.

For the third consecutive year, Children’s National Health System is co-locating its annual Symposium with The MedTech Conference, powered by AdvaMed. If you are interested in advancing innovation in pediatrics and exploring solutions to the challenges associated with device trials, we hope that you will join key industry stakeholders at the  7th Annual Pediatric Device Innovation Symposium on Sept. 22 in Boston, one day before The MedTech Conference. 

Kenton Lee was traveling through Nairobi when he had, as he says jokingly, “the only idea I’ve ever had.” He saw an orphan girl’s shoes that were way too small; someone had cut off the front so her toes could stick through. “Right there, I thought, Wouldn’t it be nice if there were shoes that could grow?” Then he went home to Boise, Idaho, developed a shoe that expands five sizes, and founded the nonprofit Because International -- which today, 12 years later, has distributed more than 250,000 pairs worldwide.

Atlas Research released its “Impact Through Innovation” report highlighting how it has helped government improve health care and address urgent health challenges through new technology, agile innovation and evidence-based solutions.

AstraZeneca Plc said on Tuesday that the U.S. Food and Drug Administration has granted fast track status for the development of its diabetes drug Farxiga to prevent heart and kidney failure in patients with chronic kidney disease (CKD).

Vaccitech, a clinical-stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases (ID), announced today that it has appointed Bill Enright as its new Chief Executive Officer (CEO). Mr. Enright succeeds Tom Evans, MD who will make a planned transition to the role of Vaccitech’s Chief Scientific Officer.

Oct 29: The Art of the #SBIR/ #STTR Deal: Best Practices in Improving Your Proposal with Olessia Smotrova, CF.APMP Fellow, Richard Bendis, Brittany Sickler, and Brandon Mason (https://expo.tedco.md)

America's Seed Fund (the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs) annually provides approximately over $3 billion in non-dilutive early-stage technology funding. The SBIR Road Tour is an opportunity for tech innovators, entrepreneurs, and researchers to learn how to access this funding, meet one-on-one with decision makers, and connect with local state innovation ecosystem members. This one-day event will provide attendees, including women and minority entrepreneurs, the opportunity to engage with representatives from various SBIR/STTR agencies.

If you’re an innovator, entrepreneur, researcher, or small technology firm, don’t miss this opportunity!

This year's QS World University Ranking results have been released, and Johns Hopkins University earned spots as the 12th best in the United States and 24th overall in the world. 

Access to capital is often considered primary challenge preventing Maryland from being the top-ranked state for biotech.

The Institute for Bioscience and Biotechnology Research (IBBR) is interested in proposals to lease a biomanufacturing facility configured to produce biologicals under cGMP conditions in compliance with FDA requirements for phase I/II clinical trials. The facility is also equipped to perform process development research, pre-clinical manufacturing for material necessary to conduct IND-enabling toxicology studies, Proof of Concept (POC) studies, and process demonstration in advance of Good Manufacturing Practices (GMP) manufacturing. IBBR is a joint research enterprise between the University of Maryland and the National Institute of Standards and Technology.

Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), today announced the securing of an $80 million Series C financing.

Leading scientists, public policy experts, and biotech industry leaders joined forces today to launch "Working to Fight AMR," a coalition working to raise public awareness of the growing threat posed by antimicrobial resistance. Working to Fight AMR will also advocate for policies that catalyze the creation of new medicines.

This article is the second in a 4-part series. Part 1 offered background on innovation districts—what they are, where they’re located, how colleges and universities relate, how P3s relate, etc. Part 3 will look at why schools might want to and might not want to consider pursuing an innovation district. Part 4 will feature an interview with Dr. Jane Talkington, scholar of innovation districts for higher ed. 

What is the difference between research parks and innovation districts?

Darmody: The terms are somewhat interchangeable, but essentially, innovation districts generally are more urban in nature with mixed-use amenities, whereas traditional research parks grew up around universities and are in rural, suburban, and urban areas, such as Boston and Austin, but also Lincoln, Nebraska, and Champaign, Illinois. When it comes down to it, though, they share a base concept: Schools and other anchor institutions are trying to build space-placed entities, and corporations come to the university for things like talent.

The record-high surge of initial public offerings (IPOs) in biopharma last year was especially good news for CEOs of many of those newly public companies.

A legal services company and a network analytics firm have been selected as the two latest participants in the Virginia Beach Entrepreneur-in-Residence program, economic development officials announced Aug. 5.

Treat yourself is a movement among millennials. But it's something that literally any age group can enjoy. These days with so much negative news, Americans are proactively looking for moments of happiness to boost their moods.

Whether you're getting a mani-pedi, playing your favorite mobile games, lounging at the pool, or visiting your favorite restaurant, there’s positive health benefits associated with giving yourself a bit of “me time.”

The mobile gaming experts at Fort Mason Games— the female run mobile gaming company that creates games designed to help people relax, destress, and socialize— know how important it is to do something nice for yourself once in a while.

That's why they commissioned a national survey to find out what Americans think about these occasional respites from routine. Mobile gaming is just one of the ways people choose to treat themselves regularly, taking time to do something special just for themselves!

Here’s some of the ways Americans treat themselves:

WASHINGTON, COLORADO, MARYLAND ARE THE TOP 3 INDULGING STATES. With 93% of Washingtonians (the state, not the district) saying they treat themselves the most, it tops the list-- though Colorado (91%) and Maryland (90%) are hot on their heels.

Kolaleh Eskandanian, PhD, is the vice president and chief innovation officer of Children's National Health System in Washington, D.C.

Here, Dr. Eskandanian outlines the big cybersecurity challenges and how she expects her role as the chief innovation officer at Children's National to evolve over the next few years.

This round nearly doubles the Sterling company’s funding raised to date.

Thursday marks the grand opening of Mayo Clinic’s new Discovery and Innovation Building, home to a pioneering technology that will increase the number of lungs available for transplant as well as a new hub for Northeast Florida’s entrepreneurs to get together, share ideas, develop new products and services, and create new companies.

The National Institutes of Health's National Cancer Institute has awarded an international group led by Johns Hopkins University researchers a $940,000 grant to study extracellular vesicles (EVs) that can be used to diagnose disease, track disease status, and potentially deliver therapies.

The company plans to double its employee count in the next two years.

The future of healthcare is precision medicine—with the potential to revolutionise healthcare and move from a one-size-fits-all approach to an individualised one, precision medicine is viewed as an emblem of a new age. 

LSIPR has discovered the top things you must consider when looking to protect your inventions in the US and/or Europe, plus one issue which matters wherever you are in the world.

Healthcare analytics compliance company Protenus raised $17 million in new funding, its leadership announced this week.

The Series C round was led by LTP, which focuses on investments in health IT and services companies. Also participating in the round were Kaiser Permanente Ventures, F-Prime Capital, Arthur Ventures, Lionbird and Providence Ventures.

Maryland's flagship university hopes to forge ties with HQ2.

REGISTER NOW FOR OUR GREATLY ANTICIPATED 4TH ANNUAL REGIONAL CONFERENCE SEPTEMBER 19, 2019

Inova Center for Personalized Health, Fairfax You’re invited to spend the day with innovative entrepreneurs, professionals and industry leaders. Discover opportunities to help you navigate through a rapidly evolving modern industry & gain access to cutting edge technologies and tools.

With an FDA approval for its pricey CAR-T therapy Yescarta under its belt and more treatments in the pipeline, Gilead’s Kite Pharma was on the hunt for a new manufacturing site to fuel those hopes. The company found it in Maryland.

REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today announced it entered into a license agreement with Pfizer Inc.

Shipping containers are continuing to prove their worth outside of transportation. From serving as a community-connecting space to an urban farm, one organization is now bringing them into education as mobile laboratories.

George Washington University just sold a portion of its royalty rights for a drug developed in its school of medicine, scoring a game-changing cash infusion it plans to reinvest in research and commercialization.

Through gene analysis, researchers have found different types of interferons in systemic lupus erythematosus (SLE) tissues and cells, such as skin and synovium. The analysis, which probed 2,000 gene expression datasets from SLE patients, specifically investigated modules of genes derived from the downstream interferon gene signature. It found enriched downstream interferon signatures that were predominately from IFNB1. These interferon signatures were higher when compared with the expression of downstream interferon signatures in kidneys with lupus nephritis, according to the study, published April 23 in Nature Communications Biology.1